Showing 1 - 6 results of 6 for search 'Swern AS', query time: 0.03s Refine Results
  1. 1
    Bailey's industrial oil and fat products/

    Bailey's industrial oil and fat products/ by Swern, Daniel, Applewhite, Thomas H.

    Published 1979
  2. 2
    Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash

    Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash by Weiss L, Gary D, Swern AS, Freeman J, Sugrue MM

    Published 2015-09-01
    Get full text
    Article
  3. 3
    Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry

    Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry by Jeff P. Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, Mecide M. Gharibo, E. Dawn Flick, Andrew Trigg, Anthony Mato

    Published 2020-07-01
    Get full text
    Article
  4. 4
    KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma by Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal, David S. Siegel

    Published 2021-06-01
    Get full text
    Article
  5. 5
    Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

    Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Aust... by Lisa Pleyer, Hartmut Döhner, Hervé Dombret, John F. Seymour, Andre C. Schuh, CL Beach, Arlene S. Swern, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva M. Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova, Wolfgang R. Sperr, Sabine Hojas, Inga M. Rogulj, Johannes Andel, Richard Greil

    Published 2017-02-01
    Get full text
    Article
  6. 6
    Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry

    Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry by Daniel A. Pollyea, Tracy I. George, Mehrdad Abedi, Rafael Bejar, Christopher R. Cogle, Kathryn Foucar, Guillermo Garcia‐Manero, David L. Grinblatt, Rami S. Komrokji, Jaroslaw P. Maciejewski, Dennis A. Revicki, Gail J. Roboz, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, Michael A. Thompson, Sandra E. Kurtin, Chrystal U. Louis, Melissa Nifenecker, E. Dawn Flick, Arlene S. Swern, Pavel Kiselev, David P. Steensma, Harry P. Erba

    Published 2020-07-01
    Get full text
    Article

Search Tools: